EXOB-001
/ EXO Biologics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 28, 2024
EVENEW: Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants
(clinicaltrials.gov)
- P1/2 | N=265 | Recruiting | Sponsor: EXO Biologics S.A.
New P1/2 trial • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1